If they proliferate but the FDA's ability to oversee them does not proliferate, you are going to have people who get hurt, Sklamberg says
CMS has not released an estimate of how many beneficiaries could be eligible for the Medicare GLP-1 Bridge, although the director of Medicare at CMS, Chris Klomp, recently stated the agency anticipates the program will start with single-digit millions of beneficiaries

If your prescription is written for type 2 diabetes: Ozempic, Mounjaro, Victoza, and Rybelsus are covered with prior authorization Prior authorization requires documentation of A1C above 7% (or above 8% for some managed care plans), trial of metformin, and contraindication screening Weight loss is considered a beneficial side effect, not the primary indication Monthly copay: $0 If your prescription is written for chronic weight management: Wegovy, Zepbound, and Saxenda are covered with prior authorization Prior authorization requires BMI criteria, comorbidity documentation (if BMI 27-29.9), step therapy completion, and contraindication screening Diabetes is a qualifying comorbidity, but the prescription must be written for obesity, not diabetes Monthly copay: $0 If your prescription is written off-label (diabetes medication prescribed for weight loss in a patient without diabetes): Denied automatically No appeal pathway unless the provider can document an FDA-approved use that the pharmacy benefit manager's system didn't recognize The diagnosis on the prescription determines the coverage pathway

When used independently, hypoglycemia rarely occurs and hypersensitivity is infrequent (69)